ArticleNanomedicine : nanotechnology, biology, and medicine2017
Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- [Research advances of liposomes and exosomes in drug delivery and biomarker screening].Se pu = Chinese journal of chromatography · 2025Review
- Tailoring biomaterials for vaccine delivery.Journal of nanobiotechnology · 2024Review
- Pathogen-binding nanoparticles to inhibit host cell infection by heparan sulfate and sialic acid dependent viruses and protozoan parasites.Smart medicine · 2024Review
- Plant-based nanoparticles targeting malaria management.Frontiers in pharmacology · 2024Review
- Current advances in nanodrug delivery systems for malaria prevention and treatment.Discover nano · 2023Review
- Heparin-Coated Dendronized Hyperbranched Polymers for Antimalarial Targeted Delivery.ACS applied polymer materials · 2023Article
- Preparation, characterization, and evaluation of eosin B-loaded nano-liposomes for growth inhibition of Plasmodium falciparum.Parasitology research · 2022Article
- Review of the Current Landscape of the Potential of Nanotechnology for Future Malaria Diagnosis, Treatment, and Vaccination Strategies.Pharmaceutics · 2021Review
- Antiparasitic Effects of Sulfated Polysaccharides from Marine Hydrobionts.Marine drugs · 2021Review
- Inhibitory Compounds Targeting Plasmodium falciparum Gyrase B.Antimicrobial agents and chemotherapy · 2021Article
- Evaluating the Anticarcinogenic Activity of Surface Modified/Functionalized Nanochitosan: The Emerging Trends and Endeavors.Polymers · 2021Review
- Liposomes for malaria management: the evolution from 1980 to 2020.Malaria journal · 2021Review
- Nanotechnology approaches for global infectious diseases.Nature nanotechnology · 2021Review
- Crustacean Waste-Derived Chitosan: Antioxidant Properties and Future Perspective.Antioxidants (Basel, Switzerland) · 2021Review
- Targeting and InhibitingACS applied materials & interfaces · 2020Article
- Heparin Administered toBiomolecules · 2020Article
- Effects of isosorbide mononitrate loaded nanoparticles conjugated with anti-Experimental and therapeutic medicine · 2020Article
- A Review of Nanotechnology for Targeted Anti-schistosomal Therapy.Frontiers in bioengineering and biotechnology · 2020Review
- Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials.Pharmaceutics · 2019Review
- An ImmunoPEGliposome for Targeted Antimalarial Combination Therapy at the Nanoscale.Pharmaceutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.